HC Wainwright & Co. Reiterates Buy on Compass Therapeutics, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Compass Therapeutics (NASDAQ:CMPX) and maintained a $10 price target.
August 04, 2023 | 2:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Compass Therapeutics (NASDAQ:CMPX) has had its 'Buy' rating reiterated and $10 price target maintained by HC Wainwright & Co.
The reiteration of a 'Buy' rating and maintenance of a $10 price target by a reputable analyst firm like HC Wainwright & Co. is a positive signal for Compass Therapeutics. This could potentially lead to increased investor confidence and a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100